Determinants of 1-Year Unfavorable Outcomes of Intravenous Alteplase Thrombolysis for Acute Ischemic Stroke
Clinical and Applied Thrombosis/Hemostasis · 2023
DOI: 10.1177/10760296231187616 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical and Applied Thrombosis/Hemostasis, 2023. Verfasst von Mingfeng Zhai und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei, China. Hauptthemen laut MEDLINE: Stroke, Ischemic Stroke, Atrial Fibrillation, Brain Ischemia. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: the Fuyang Health and Health Commission Project, the National Natural Science Foundation of China.
Themen: Schlaganfall
Abstract (Originalsprache)
Objective
Intravenous thrombolytic therapy has become the standard of treatment for eligible patients with ischemic stroke. However, outcomes after receiving intravenous thrombolytic therapy vary widely. This study aims to investigate determinants of 1-year clinical outcomes of intravenous thrombolytic therapy for patients with acute ischemic stroke.
Methods
In a prospective, observational study, patients with acute ischemic stroke treated with intravenous thrombolysis were consecutively included, and clinical information and laboratory data were collected. The patients were followed up for 12 months after onset, and the 1-year clinical outcome was evaluated using modified Rankin Scale scores. A score ≥ 3 was defined as unfavorable functional outcome. Univariate and multivariate logistic regressions were used to assess the determinants of the 1-year clinical outcomes of intravenous thrombolysis for acute ischemic stroke.
Results
A total of 222 patients with intravenous thrombolysis were enrolled, and we identified 58 patients (26.1%) had unfavorable functional outcomes. Multivariate logistic regression analysis revealed that mean platelet volume-to-lymphocyte ratio (MPVLR) (odds ratio [OR] = 1.114, 95% confidence interval [CI]: 1.024–1.211, P = .012), atrial fibrillation (OR = 2.553, 95% CI: 1.086-6.002, P = .032), symptomatic stenosis occlusion (OR = 2.547, 95% CI: 1.269-5.110, P = .009), and baseline National Institutes of Health Stroke Scale (NIHSS) score (OR = 1.141, 95% CI: 1.074-1.212, P < .001) were independent predictors of unfavorable functional outcomes at 1 year.
Conclusions
In patients receiving intravenous thrombolysis, we found that MPVLR, atrial fibrillation, symptomatic stenosis occlusion, and baseline NIHSS score were significant predictors of unfavorable functional outcomes at 1 year.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
- Department of Neurology, The Affiliated Fuyang People's Hospital of Anhui Medical University, Fuyang, China.
- Department of Pediatrics, The First Affiliated Hospital of Anhui Medical University, Anhui Public Health Clinical Center, Hefei, China.
- Anhui Public Health Clinical Center, Hefei, China.
ORCID-Profile: Mingfeng Zhai
Förderung
- the Fuyang Health and Health Commission Project
- the National Natural Science Foundation of China
Zitieren
APA
Zhai, M., Yang, J., Cao, X., Li, Y., Xu, H., & Wang, Y. (2023). Determinants of 1-Year Unfavorable Outcomes of Intravenous Alteplase Thrombolysis for Acute Ischemic Stroke. Clinical and Applied Thrombosis/Hemostasis. https://doi.org/10.1177/10760296231187616
Vancouver
Zhai M, Yang J, Cao X, Li Y, Xu H, Wang Y. Determinants of 1-Year Unfavorable Outcomes of Intravenous Alteplase Thrombolysis for Acute Ischemic Stroke. Clinical and Applied Thrombosis/Hemostasis. 2023. doi:10.1177/10760296231187616
BibTeX
@article{Zhai2023,
author = {Zhai, Mingfeng and Yang, Jinwei and Cao, Xiaoyan and Li, Yingying and Xu, Hui and Wang, Yu},
title = {Determinants of 1-Year Unfavorable Outcomes of Intravenous Alteplase Thrombolysis for Acute Ischemic Stroke},
journal = {Clinical and Applied Thrombosis/Hemostasis},
year = {2023},
doi = {10.1177/10760296231187616}
}
EUVIMED